WHAT IS CLAIMED IS:

1. A crystalline form of the compound of the formula:



characterized by an X-ray powder diffraction (XRPD) pattern that comprises peaks at 11.2, 12.9, 15.5, 17.8, 19.1, 20.0 and 20.7 degrees 2θ (± 0.1 degrees 2θ), wherein said XRPD is made using $CuK_{\alpha 1}$ radiation.

2. The crystalline form in accordance with claim 1, characterized by an ~~X-ray powder diffraction~~ (XRPD) pattern that further comprises one or more peaks at 5.4, ~~11.2,~~ 11.3, 11.9, ~~12.9, 15.5,~~ 16.3, ~~17.8, 19.1, 20.0,~~ 20.6, ~~20.7,~~ 21.2, 22.8, 23.0, 23.4, 23.6, 23.9, 24.7, 25.4, 25.8, 27.8 and 28.2 degrees 2θ (± 0.1 degrees 2θ), wherein said XRPD is made using $CuK_{\alpha 1}$ radiation.

~~3. The crystalline form in accordance with claim 2, characterized by an XRPD that comprises peaks at 12.9, 19.1 and 20.7 degrees 2θ (± 0.1 degrees 2θ), wherein said XRPD is made using $CuK_{\alpha 1}$ radiation.~~

~~4. The crystalline form in accordance with claim 2, characterized by an XRPD that comprises peaks at 11.2, 12.9, 15.5, 17.8, 19.1, 20.0 and 20.7 degrees 2θ (± 0.1 degrees 2θ), wherein said XRPD is made using $CuK_{\alpha 1}$ radiation.~~

~~5~~3. The crystalline form in accordance with claim 2, characterized by an XRPD pattern that comprises peaks at 11.2, 12.9, 15.5, 17.8, 19.1, 20.0, 20.6, 20.7, 21.2 and 22.8 degrees 2θ (± 0.1 degrees 2θ), wherein said XRPD is made using $CuK_{\alpha 1}$ radiation.

~~6~~4. The crystalline form in accordance with claim 2, characterized by an XRPD pattern that comprises peaks at 5.4, 11.2, 11.9, 12.9, 15.5, 16.3, 17.8, ~~and~~ 19.1, 20.0 and 20.7 degrees 2θ (± 0.1 degrees 2θ), wherein said XRPD is made using $CuK_{\alpha 1}$ radiation.

~~7. The crystalline form in accordance with claim 2, characterized by an X-ray powder diffraction (XRPD) pattern that comprises peaks at 11.2 and 12.9 degrees 2θ (± 0.1 degrees 2θ), wherein said XRPD is made using $CuK_{\alpha 1}$ radiation.~~

~~8~~5. The crystalline form in accordance with claim 1, characterized by ~~the XRPD peaks substantially in accordance with those of **Figure 2**~~an XRPD pattern that comprises peaks at 5.4, 10.7, 11.2, 11.3, 11.9, 12.9, 14.7, 15.0, 15.5, 16.1, 16.3, 17.8, 18.7, 19.1, 20.0, 20.6, 20.7, 21.2, 21.6, 22.4, 22.8, 23.0, 23.4, 23.6, 23.9, 24.7, 24.9, 25.4, 25.8, 27.0, 27.5, 27.8, 28.2, 28.9, 29.0, and 29.6 degrees 2θ (± 0.1 degrees 2θ), wherein said XRPD is made using $CuK_{\alpha 1}$ radiation.

~~96~~. The crystalline form in accordance with claim 1, characterized by a Raman spectra that comprises one or more peaks at about 353, 688, 825, 1178, 1205, 1212, 1608, 2945, 3010 and 3063 cm^{-1}.

~~107~~. The crystalline form in accordance with claim 1, characterized by a Raman spectra that comprises peaks at about 353, 688, and 825 cm^{-1}.

~~118~~. The crystalline form in accordance with claim 1, characterized by the Raman ~~peaks substantially in accordance with those of **Figure 4**~~spectra that comprises peaks at about 144, 189, 216, 226, 284, 315, 353, 387, 419, 432, 449, 503, 530, 565, 594, 638, 688, 716, 728, 755, 790, 825, 850, 884, 901, 919, 934, 974, 984, 1014, 1030, 1052, 1070, 1120, 1134, 1178, 1205, 1212, 1229, 1302, 1323, 1343, 1380, 1422, 1438, 1457, 1572, 1585, 1608, 2844, 2919, 2945, 2963, 2997, 3010, 3028, 3051, 3063, 3085, and 3095 cm^{-1}.

~~129~~. The crystalline form in accordance with claim 1, characterized by

an ~~X-ray powder diffraction (~~XRPD~~)~~ pattern that further comprises one or more peaks at 5.4, ~~11.2,~~ 11.3, 11.9, ~~12.9, 15.5,~~ 16.3, ~~17.8, 19.1, 20.0,~~ 20.6, ~~20.7,~~ 21.2, 22.8, 23.0, 23.4, 23.6, 23.9, 24.7, 25.4, 25.8, 27.8 and 28.2 degrees 2θ (± 0.1 degrees 2θ), wherein said XRPD is made using $CuK_{\alpha 1}$ radiation; and

a Raman spectra that comprises one or more peaks at about 353, 688, 825, 1178, 1205, 1212, 1608, 2945, 3010 and 3063 cm^{-1}.

~~1310~~. The crystalline form in accordance with claim ~~129~~, characterized by

an ~~X-ray powder diffraction (~~XRPD~~)~~ pattern that further comprises one or more peaks at ~~11.2, 12.9, 15.5, 17.8, 19.1, 20.0,~~ 20.6, ~~20.7,~~ 21.2, ~~and~~ 22.8 and 28.2 degrees 2θ (± 0.1 degrees 2θ), wherein said XRPD is made using $CuK_{\alpha 1}$ radiation; and

a Raman spectra that comprises one or more peaks at about 353, 688, and 825 cm^{-1}.

~~1411~~. The crystalline form in accordance with claim 1, characterized by a differential scanning calorimetry (DSC) endotherm at about 136° C.

~~1512~~. The crystalline form in accordance with claim 1, characterized by the unit cell data ~~substantially in accordance with **Figure 7**~~comprising

a family and space group of monoclinic $P2_1$ (#4),

a Z'/Z of 1/2,

an *a* of 7.960 Å,

a *b* of 8.860 Å,

a *c* of 16.560 Å,

an α of 90°,

a β of 95.71°,

a γ of 90°,

a volume of 1162.1 $Å^3$/cell,

a V/Z of 581.1 $Å^3$/asymmetric unit,

an assumed composition of $C_{24}H_{29}O_7Cl$, and

a density of 1.329 g/cm^3.

~~16~~13. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a crystalline form of the compound (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-(2-cyclopropoxyethoxy)benzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2*H*-pyran-3,4,5-triol.

~~17~~14. A crystalline form of a compound of claim 1 which is isotopically labeled.

~~18~~15. A method for making a crystalline form of the compound of claim 1, said method comprising the steps:

(a) combining (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-(2-cyclopropoxyethoxy)benzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2*H*-pyran-3,4,5-triol bis(L-proline) complex and a suitable solvent with mixing to form a solution;

(b) adding a precipitating solvent to said solution to provide a mixture; and

(c) isolating said crystalline form from said mixture.

~~19~~16. The method of claim ~~18~~15, wherein the solvent of step (a) is selected from the group consisting of methanol and ethanol.

~~20~~17. The method of claim ~~18~~15, wherein the solvent of step (a) is methanol.

~~21~~18. The method of claim ~~18~~15, wherein the precipitating solvent is water.

~~22~~19. The method of claim ~~18~~15, wherein the solvent of step (a) is methanol and the precipitating solvent is water.

~~23~~20. The method of claim ~~22~~19, wherein the ratio of methanol to water in the mixture of step (b) is from about 1:1 to about 1:9 by volume.

~~24~~21. The method of claim ~~22~~19, wherein the ratio of methanol to water in the mixture of step (b) is about 1:5 by volume.

~~25~~22. The method of claim ~~18~~15, wherein the ratio of complex to solvent and precipitating solvent in the mixture of step (b) is from about 1:10 to about 1:25 (w/v).

~~26~~23. The method of claim ~~18~~15, wherein the mixture of step (b) further comprises a base.

~~27~~24. The method of claim ~~18~~15, wherein the mixture of step (b) further comprises a salt.

2825. The method of claim 1815, wherein the mixture of step (b) further comprises a seed crystal of the compound of claim 1.

2926. A method for making a crystalline form of the compound of claim 1, said method comprising the steps:

(a) combining (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-(2-cyclopropoxyethoxy)benzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2*H*-pyran-3,4,5-triol and a suitable solvent with mixing to form a solution; and

(b) isolating said crystalline form from said solution.

3027. The method of claim 2926, said method comprising the steps:

(a) combining amorphous (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-(2-cyclopropoxyethoxy)benzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2*H*-pyran-3,4,5-triol and a suitable solvent with mixing to form a solution; and

(b) adding a precipitating solvent to said solution to form a mixture; and

(c) isolating said crystalline form from said mixture.

3128. The method of claim 2926, further comprising adding a precipitating solvent to said solution.

3229. The method of claim 3128, wherein the solvent of step (a) is selected from the group consisting of methanol and ethanol.

3330. The method of claim 3128, wherein the solvent of step (a) is methanol.

3431. The method of claim 3128, wherein the precipitating solvent is water.

3532. The method of claim 3128, wherein the solvent of step (a) is methanol and the precipitating solvent is water.

3633. The method of claim 3532, wherein the ratio of methanol to water in the mixture of step (b) is from about 1:1 to about 1:9 by volume.

3734. The method of claim 3532, wherein the ratio of methanol to water in the mixture of step (b) is about 1:5 by volume.

3835. The method of claim 3128, wherein the ratio of complex to solvent and precipitating solvent in the mixture of step (b) is from about 1:1 to about 1:9 by volume.

3936. The method of claim 3128, wherein the solution further comprises a seed crystal of the compound of claim 1.

4037. The method of claim 3128, wherein the (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-(2-cyclopropoxyethoxy)benzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2*H*-pyran-3,4,5-triol is amorphous (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-(2-cyclopropoxyethoxy)benzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2*H*-pyran-3,4,5-triol.

4138. The method of claim 4037, wherein the amorphous (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-(2-cyclopropoxyethoxy)benzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2*H*-pyran-3,4,5-triol is prepared from (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-(2-cyclopropoxyethoxy)benzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2*H*-pyran-3,4,5-triol bis(L-proline) by

(a2) combining (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-(2-cyclopropoxyethoxy)benzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2*H*-pyran-3,4,5-triol bis(L-proline) complex and a suitable solvent mixture with mixing to form a solution; and

(a3) isolating amorphous (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-(2-cyclopropoxyethoxy)benzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2*H*-pyran-3,4,5-triol from said solution of step (a2).

4239. The method of claim 4138, wherein said solvent mixture of step (a2) comprises an organic solvent and an aqueous solvent.

4340. The method of claim 4138, wherein said solvent mixture of step (a2) comprises ethyl acetate and water.

4441. Use of a composition comprising a crystalline form of the compound of claim 1 in the manufacture of a medicament for treating a disease or condition selected from the group consisting of type 1 diabetes mellitus, type 2 diabetes mellitus, hyperglycemia, diabetic complications, insulin resistance,

metabolic syndrome, hyperinsulinemia, hypertension, hyperuricemia, obesity, edema, dyslipidemia, chronic heart failure, atherosclerosis, and cancer.

~~45. Use of a composition comprising a crystalline form of the compound of claim 1 in the manufacture of a medicament for treating a disease or condition affected by inhibiting SGLT2.~~